For appointments

Call the office

Folsom, California Office: 916-983-4444

Call Now

Close

WHO:

Dr. Gish is a Hepatologist specializing in all forms of liver disease, liver cancer and liver transplant. Dr. Gish has partnered with TeleMed2U to provide telemedicine consultative services for patients with liver disease.

WHAT:

TeleMed2U is a telemedicine-based multi-specialty clinical practice increasing access to specialist providers providing, “healthcare anywhere and everywhere.” The telemedicine consultation will be conducted through our HIPAA and HITECH compliant platform. Connectivity testing will be done in advance to ensure you can connect via our telemedicine platform. Following the consultation, a clinical note will be provided including a summary of your liver consultation with Dr. Gish and his consultative recommendations.

COST:

Payment will be processed through an online secure transaction portal. The fees for consultative services are:

Initial 60 minute consultation per patient: $500.00
Follow Up 30 minute consultation per patient: $300.00

NEXT STEPS:

If you’d like to continue, please click Next to complete the form and we will contact you to schedule connectivity testing. During the test you will have the opportunity to determine the method of providing medical records, discuss appointment availability as well as discuss any additional questions that you have. If you are a healthcare facility interested in services, please complete the form and we can discuss the options that are right for you and your patients.

Email

Subject

Country

You should be aware of the general risks of transmitting information over the Internet, which may not use encryption. You should therefore not share any personal medical information that you would wish to be held confidential in a physician/patient or similar clinical relationship.

The information contained on this website is not intended, should not substitute for, or be used instead of, a clinical or therapeutic relationship with a health care professional who is fully familiar with the specifics of your case. The information on this site may assist you in your personal, general research but none of it constitutes the practice of medicine or any other health care profession.

Nothing in this site is intended as a recommendation or endorsement of any specific tests, products, procedures, healthcare provider, opinions, or other information that may be mentioned in this site. Any reliance on any information provided by the website personnel, others appearing on the site at the invitation of the website and/or other visitors to the site is solely at the user's risk.

E-mail correspondence with Dr. Robert G. Gish Consultants, LLC or any of its employees, or agents, does not create a physician/patient relationship between us or cause Dr. Gish to create or retain any medical records about you, monitor your care, or communicate with your own health care provider.

Always seek the advice of your physician or other qualified health care provider with any questions you have regarding your medical care. If you suspect that you may have a medical condition, or are seeking medical advice or treatment, we recommend that you consult a qualified health professional as soon as possible.

Powered by

Close Form

Dr. Gish Urges Asian Americans to Test for Hepatitis B

May 14, 2016

APHF Medical Director Robert Gish said Hepatitis B and C are the leading causes of liver transplants and liver cancer in the United States. Hepatitis B infects 2 million. Hepatitis C infects 5 million people. Those are big numbers,” he said.

The viruses that can lead to scarring of the liver and eventually liver cancer often go unnoticed by carriers, because acute symptoms of Hepatitis B and C resemble flu-like symptoms. Both Hepatitis B and C are bloodborne infections and can only be passed on through contact with blood. Transmission of the virus happens most frequently through blood infusions and exposure to blood, but transmission through sex is also possible.

Globally, Hepatitis B infection has concentrated in Asia and Southeast Asia. In the United States, first and second generation Asian American and Pacific Islander communities are most at risk of having and contracting the virus.

While not curable, there is a vaccine that can prevent Hepatitis B in those not exposed to the virus, and the virus can be suppressed and controlled with medication to decrease the risk of liver cancer.

APHF Executive Director Binh Tran said a stigma is associated with Hepatitis B that leads to discrimination and has created problems trying to control the disease. “Oftentimes people don’t talk about their diseases. They are afraid their bosses at their place of work will [reveal them] and they will lose their job,” she said.

The Centers for Disease Control and Prevention partners with community health organizations to help contain the infection. The APHF grew out of a community clinic and collaborates with the UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences. Together, they provide screening services to those communities most at risk for Hepatitis B and C, hypertension and osteoporosis. The collaboration also allows UC San Diego students to conduct research on the communities they work in.

Dr. Gish appealed to the community to refer their friends and family to get tested at community screenings or by their medical providers.

“We really want to link people to care, because our ultimate goal is to eradicate Hepatitis B and C,” he said. “That can happen in the next few decades. It’s going to take time, and work, and collaboration.”

https://www.youtube.com/watch?v=6GWxvem_GIk

Metadata